Drug intelligence / Profile preview

Nuretin

Development stage: Unknown
Lead developer: PRN Vision Group
Modality: Small Molecules
Administration: Oral

Overview

Nuretin (also stylized as Nūretin) is a specialized omega-3 dietary supplement developed by PRN Therapeutics (PRN Vision) for the dietary management of patients with diabetic retinopathy and other retinal conditions. It is formulated as a 'medical food' and contains a high-concentration, re-esterified triglyceride (rTG) form of omega-3 fatty acids, providing 1,000 mg of docosahexaenoic acid (DHA) and 200 mg of eicosapentaenoic acid (EPA) in a 1:5 ratio. DHA is a critical structural component of the retina, and Nuretin is intended to support retinal health and help reduce the risk of disease progression. The product is manufactured in Norway according to cGMP standards and is typically available through a physician's recommendation.

Brand names: NuretinNūretin
Other names: PRN Nuretin

Beyond the preview

Go deeper on Nuretin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuretin.

Explore the full profile